Quarterly report pursuant to Section 13 or 15(d)

SHARE CAPITAL (Details)

v3.8.0.1
SHARE CAPITAL (Details) - USD ($)
6 Months Ended 12 Months Ended
Sep. 30, 2017
Mar. 31, 2017
Opening Balance $ 24,150,695 $ 5,399,896
Shares issued on acquisition (Note 3)   23,177,000
Options exercised   18,166
Warrants exercised 1,125,038 $ 40,195
Cashless exercise of warrants (iv) (in shares)   51,249
Cashless exercise of warrants (iv)   $ 0
Closing Balance $ 20,873,148 $ 24,150,695
Exchangable Shares [Member]    
Opening Balance (in shares) 47,909,336 50,000,000
Opening Balance $ 47,910 $ 50,000
Converted into common shares (in shares) 0 (2,090,664)
Converted into common shares $ 0 $ (2,090)
Closing Balance (in shares) 47,909,336 47,909,336
Closing Balance $ 47,910 $ 47,910
Common Shares [Member]    
Opening Balance (in shares) 48,885,107 22,591,292
Opening Balance $ 48,884 $ 22,591
Shares issued on acquisition (Note 3) $ 0 $ 23,650
Shares issued on acquisition (Note 3) (in shares) 0 23,650,000
Shares issued to exchangeable shareholders (in shares) 0 2,090,664
Shares issued to exchangeable shareholders $ 0 $ 2,090
Shares issued for services (in shares) 0 217,047
Shares issued for services $ 0 $ 217
Options exercised (in shares) 0 110,096
Options exercised $ 0 $ 110
Warrants exercised $ 5,000 [1] $ 175
Warrants exercised (in shares) 5,000,172 [1] 174,759
Cashless exercise of warrants (iv) (in shares) 0 51,249
Cashless exercise of warrants (iv) $ 0 $ 51
Closing Balance (in shares) 53,885,279 48,885,107
Closing Balance $ 53,884 $ 48,884
Common Shares And Exchangeable Shares [Member]    
Opening Balance (in shares) 96,794,443  
Opening Balance $ 96,794  
Closing Balance (in shares) 101,794,615 96,794,443
Closing Balance $ 101,794 $ 96,794
[1] During the six months period ended September 30, 2017, the Company consummated an offer to amend and exercise to its warrant holders, enabling them to exercise their outstanding warrants for $0.25 per share, and as a result, 5,000,172 common shares were issued for net proceeds of $1,125,038 (Note 12).